Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Valutare la sicurezza e l'efficacia di AccuraSee™ IOPCL per l'impianto secondario nel sacco capsulare per migliorare la visione da vicino e/o intermedia dopo un precedente intervento di cataratta

13 novembre 2026 aggiornato da: OnPoint Vision Inc

Studio di fattibilità iniziale per valutare la sicurezza e l'efficacia di AccuraSee™ IOPCL per l'impianto secondario nel sacco capsulare per migliorare la visione da vicino e/o intermedia a seguito di un precedente intervento di cataratta

This is a study to evaluate the safety and effectiveness of the AccuraSee™ intraocular pseudophakic capsular lens (IOPCL) to improve near and/or intermediate vision following previous cataract surgery.

Panoramica dello studio

Stato

Reclutamento

Intervento / Trattamento

Descrizione dettagliata

The objective of this study is to provide preliminary evidence of the safety and efficacy of the AccuraSee intraocular pseudophakic capsular lens (IOPCL) in qualified subjects previously implanted with an Alcon monofocal intraocular lens model SN60WF, SA60WF, or SA60AT, Johnson and Johnson model ZCB00, or Zeiss model CT LUCIA 602 who desire near vision of 20/32 or better via a myopic shift in the eye to be treated.

Tipo di studio

Interventistico

Iscrizione (Stimato)

10

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

22 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

Sì

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

All ocular eligibility criteria refer to the study (non-dominant) eye only unless otherwise noted.

  1. Subjects aged 22 years and older.
  2. Subjects who have had cataract surgery with an Alcon monofocal intraocular lens model SN60WF, SA60WF, or SA60AT (with a lens power from 10.0D to 30.0D), or Johnson and Johnson monofocal lens model ZCB00 (with a lens power from 10.0D to 26.0D), or Zeiss monofocal lens model CT LUCIA 602 (with a lens power from 10.0D to 19.0D) clearly evidenced by photographic documentation with one of the following: patient medical record, clinic chart with labeling attached, surgical record with labeling attached, or patient identification card with make, model, power and serial number.
  3. Subjects who have had cataract surgery at least 6 months from the planned date of IOPCL surgery.
  4. Subjects who require a reading add of +1.50 to +2.50 to achieve an BCNVA of 20/32 or better.
  5. Subjects with uncorrected near visual acuity (UCNVA) 20/50 or worse.
  6. Subjects with best corrected distance visual acuity (BCDVA) 20/25 or better in both eyes.
  7. Subjects with uncorrected distance visual acuity (UCDVA) 20/25 or better in fellow eye.
  8. Subjects with best corrected near visual acuity (BCNVA) 20/32 or better.
  9. Subjects with a manifest refraction spherical equivalent (MRSE) in the study eye between +0.25D and +1.50D.
  10. Subjects with <1D of refractive cylinder determined by keratometry readings.
  11. Subjects with a minimum endothelial cell count of 1800 cells/mm2.
  12. Subjects with a tear break up time (TBUT) ≥ 7 seconds.
  13. Subjects with a documented monovision tolerance, or who have successfully completed a 1-week contact lens trial prior to implantation with the IOPCL.
  14. For subjects who are contact lens wearers, discontinuation of lens usage prior to the preoperative visit (at least 2 weeks for subjects using soft contact lenses and at least 3 weeks for hard or rigid gas permeable (RGP) lenses) except as required to test monovision acceptance.
  15. For subjects who are contact lens wearers, two central keratometry readings with regular mires and two manifest refractions taken at least one week apart (keratometry values must not differ by more than ±0.50D in either principal meridian in the eye to be treated).
  16. Subjects able to comprehend and sign a statement of informed consent.
  17. Subjects willing and able to complete all required postoperative visits.
  18. Subjects willing to abstain from pursuing any other refractive surgery for the duration of the study.

Exclusion Criteria:

  1. Subjects who have had cataract surgery with other than a monofocal posterior chamber intraocular lens (PCIOL).
  2. Subjects who have had previous laser refractive surgery.
  3. Subjects who have had cataract surgery with an Alcon monofocal intraocular lens model SN60WF, SA60WF, or SA60AT (with a lens power below 10.0D or greater than 30.0D), or Johnson and Johnson monofocal intraocular lens model ZCB00 (with a lens power below 10.0D or greater than 26.0D) or Zeiss monofocal lens model CT LUCIA 602 (with a lens power below 10.0D or greater than 19.0D).
  4. Subjects who were treated with a PCIOL in a manner that is not consistent with the labeling, contraindications, or indications for use statement.
  5. Subjects whose continuous curvilinear capsulorhexis is less than 4.5 mm or more than 6.0 mm in size at the time of the preoperative visit.
  6. Subjects who have had a Nd:YAG capsulotomy less than 1 month prior to the planned date of the IOPCL surgery.
  7. Subjects with a mesopic non-dilated pupil of greater than 5.5mm.
  8. Subjects with a mesopic dilated pupil of less than 7.0 mm.
  9. Subjects who have 1D or more of refractive cylinder determined by keratometry readings.
  10. Subjects who had cataract surgery less than 6 months from the planned date of the IOPCL surgery.
  11. Subjects whose PCIOL is substantially decentered (> 1.0 mm).
  12. Subjects with anterior capsule fibrosis and phimosis that, in the opinion of the investigator, may confound the outcome or increase the risk to the subject (e.g., excessive capsule contraction potentially obstructing the visual axis or causing late secondary complications to the PCIOL such as pseudophacodenesis and IOL tilt, decentration, or dislocation due to zonular laxity, weakness or dehiscence).
  13. Subjects with capsular instability.
  14. Subjects with an anterior capsular defect.
  15. Subjects with posterior capsular defect < 0.5 mm from the edge of the existing IOL (caused by Nd:YAG capsulotomy).
  16. Subjects with a tear or rent in the anterior or posterior capsule.
  17. Subjects with any corneal pathology that is either progressive or sufficient to reduce BCDVA to 20/25 or worse.
  18. Subjects with any corneal abnormality, other than regular corneal astigmatism, that prevents accurate assessment of fluorescein tear break up time or, in the opinion of the investigator, would confound the outcome(s) of the study.
  19. Subjects with active moderate to severe meibomian gland dysfunction.
  20. Subjects with clinically severe corneal dystrophy (e.g., epithelial, stromal, or endothelial dystrophy).
  21. Subjects with diagnosed degenerative visual disorders (e.g., macular degeneration or other retinal disorders) that would reduce BCDVA to 20/25 or worse.
  22. Subjects with recurrent severe anterior or posterior segment inflammation of unknown etiology.
  23. Subjects with microphthalmos.
  24. Subjects with previous retinal detachment.
  25. Subjects with diabetic retinopathy.
  26. Subjects with iris neovascularization.
  27. Subjects with a history of steroid-responsive rise in intraocular pressure (IOP), uncontrolled glaucoma or preoperative IOP >21 mmHg.
  28. Subjects with amblyopia in either eye.
  29. Subjects who have current or historical significant binocular muscle imbalances or intermittent tropias and/or fail the cover test.
  30. Subjects who fail to demonstrate normal perception at near (33 cm) on the Worth 4 Dot Binocular Test for binocular function (using best corrected visual acuity).
  31. Subjects who fail to demonstrate at least gross stereopsis (i.e., pinching fly's wings in front of test booklet) with best corrected visual acuity on the Titmus Stereo Test (at near).
  32. Subjects with a fundus not visible.
  33. Subjects with aniridia.
  34. Subjects with optic nerve atrophy.
  35. Subjects with damaged or incomplete zonules.
  36. Subjects with inadequate anterior leaflet coverage of the PCIOL (defined as less than 0.5 mm of anterior leaflet of capsule above where the haptics will reside).
  37. Subjects with damage to the PCIOL.
  38. Subjects with a known history of pseudoexfoliation, or pseudoexfoliation diagnosed at the preoperative visit or prior to IOPCL implantation.
  39. Subjects with acute, chronic or uncontrolled systemic or ocular disease that in the opinion of the investigator would increase the operative risk or confound the outcome(s) of the study.
  40. Subjects taking medications that, in the opinion of the investigator, may confound the outcome or increase the risk to the subject (tamsulosin hydrochloride (Flomax)) or taking other medications with similar side effects (floppy iris syndrome).
  41. Subjects participating in any other ophthalmic drug or device trial during the time of this investigation.
  42. Subjects who are pregnant or nursing women; or women of child bearing age not using medically acceptable contraceptives.
  43. Subjects with certain occupational and environmental visual demands (i.e. piloting an airplane, working on and operating dangerous machinery) in the opinion of the investigator would increase the post-operative risk.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Lente capsulare intraoculare pseudofachica AccuraSee™ (IOPCL)

Intraocular pseudophakic capsular lens (IOPCL)

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Improvement in uncorrected near visual acuity (UCNVA) at 40 cm/16 inches
Lasso di tempo: 12 months

Improvement in uncorrected near visual acuity (UCNVA) (at 40 cm/16 inches) at 12 months postoperatively. At least 75% of treated eyes should achieve an uncorrected near visual acuity (UCNVA) of 20/32 or better.

12 months

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Improvement in uncorrected intermediate visual acuity (UCIVA) (at 66 cm/26 inches)
Lasso di tempo: 12 months

Improvement in uncorrected intermediate visual acuity (UCIVA) at 66 cm/26 inches at 12 months postoperatively. At least 75% of treated eyes should achieve a UCIVA of 20/40 or better.

12 months
Preservation of best corrected distance visual acuity (BCDVA)
Lasso di tempo: 12 Months

Proportion of eyes (< 5%) that lose two or more lines of best corrected distance visual acuity (BCDVA) (≥ 10 letters on the Early Treatment for Diabetic Retinopathy Study [ETDRS] chart).

12 Months
Successful delivery of the intraocular pseudophakic capsular lens (IOPCL)
Lasso di tempo: Postoperatively from 7-14 days visit through 12 months visit

Successful delivery of the intraocular pseudophakic capsular lens (IOPCL) (defined as no capsular tear, no visible damage to either the posterior chamber intraocular lens [PCIOL] or the IOPCL, and adequate leaflet coverage of all IOPCL haptic tabs [≥ 0.5 mm of anterior leaflet of capsule above where the haptics reside]).

Postoperatively from 7-14 days visit through 12 months visit
PCIOL Long-term adherence and positional stability (tilt)
Lasso di tempo: Postoperatively from 30-60 days visit through 12 months visit

Minimal tilt of the posterior chamber intraocular lens (PCIOL) confirmed via Anterion® AS-OCT (defined as ≤ 10 degrees between the postoperative tilt of the PCIOL and the pre-operative tilt of the PCIOL).

Postoperatively from 30-60 days visit through 12 months visit
Intraocular Pseudophakic Capsular Lens (IOPCL) Long-term adherence and positional stability (tilt)
Lasso di tempo: Postoperatively from 30-60 days visit through 12 months visit

Minimal tilt of the intraocular pseudophakic capsular lens (IOPCL) (using the posterior chamber intraocular lens [PCIOL] as a reference point) confirmed via Anterion® AS-OCT (defined as ≤ 10 degrees between the post-operative tilt of the PCIOL and the postoperative tilt of the IOPCL).

Postoperatively from 30-60 days visit through 12 months visit
PCIOL/IOPCL Complex Long-term adherence and positional stability (decentration)
Lasso di tempo: Postoperatively starting at 7-14 days through 12 months

Decentration of the posterior chamber intraocular lens/intraocular pseudophakic capsular lens (PCIOL/IOPCL complex) (defined as uniform exposed area of the PCIOL outside of the IOPCL at the vertical and horizontal meridians between ≥ 0.5 mm and ≤ 1.0 mm.

Postoperatively starting at 7-14 days through 12 months
Intraoperative and postoperative adverse events
Lasso di tempo: Intraoperative and Postoperative through 12 months

Characterization and incidence of cumulative and persistent intraoperative and post-operative adverse events.

Intraoperative and Postoperative through 12 months
Secondary Surgical Interventions (SSIs)
Lasso di tempo: Postoperative through 12 months

Incidence of secondary surgical interventions (SSIs) (e.g., removal of interlenticular opacity, repositioning of intraocular pseudophakic capsular lens [IOPCL], explant of IOPCL, repositioning of posterior chamber intraocular lens [PCIOL]) (excluding neodymium-doped yttrium aluminum garnet [Nd:YAG] treatments for posterior capsule opacification (PCO).

Postoperative through 12 months
Endothelial Cell Counts
Lasso di tempo: Postoperatively beginning with 120-180 days through 12 months

Endothelial Cell Counts (mean loss, minimum, maximum, and quartiles of endothelial cell density [ECD] loss)

  • Percent of eyes that lose 20% or more ECD
  • Percent of eyes that lose 25% or more ECD
  • Percent of eyes that lose 30% or more ECD
Postoperatively beginning with 120-180 days through 12 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

23 settembre 2024

Completamento primario (Stimato)

1 dicembre 2027

Completamento dello studio (Stimato)

1 dicembre 2027

Date di iscrizione allo studio

Primo inviato

26 settembre 2024

Primo inviato che soddisfa i criteri di controllo qualità

1 ottobre 2024

Primo Inserito (Effettivo)

3 ottobre 2024

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

16 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

13 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Termini MeSH pertinenti aggiuntivi

Altri numeri di identificazione dello studio

  • CIIPCL-022R

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

Sì

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi